In agreement with the crucial role of IDH1 in anti-oxidant defenses through NADPH production, recent studies have demonstrated that its genetic inhibition reduces GBM growth and may significantly improve the efficacy of conventional GBM therapies [38, 39] (Table 1). Here, IDH1 is linked to glioblastoma.